AbOliGo (Cambridge UK, founded 2024) is developing a revolutionary platform for rapid, small-scale production of antibody-oligonucleotide conjugates (AOCs), addressing a critical bottleneck in multiplexing. AOCs are transformative tools that combine antibodies' exquisite targeting specificity with oligonucleotides' properties - DNA amplification and molecular barcoding, enabling unlimited multiplexing. However, while there are approximately 7 million commercially available antibodies, only ~0.03% are offered as AOCs.
Recognizing the growing demand for AOCs, we aim to innovate and re-imagine the manufacturing process through three key technological advancements:
Scale - A novel conjugation methodology that enables production at µg scale.
Quality – Develop a QC quantitative release criteria, guaranteeing batch consistency.
Fast – Manufacture and deliver AOCs from a large portfolio within days.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Babraham Research Campus, Cambridge,cb22 3at,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.aboligo.com/
- Keywords
- antibody conjugation, AOCs, Antibody-Oligo Conjugates, Proteomics, muliplex protein assays.
- HQ
- Cambridge
Aboligo Questions
Aboligo's website is https://www.aboligo.com/
Aboligo's LinkedIn profile is https://uk.linkedin.com/company/aboligo
Aboligo has
4 employees.
View email and phone details for 4
employees at Aboligo.
Aboligo's industry is
Biotechnology Research
Aboligo's categories are Biotechnology Research
Aboligo's founding year is 2024
